The University of Michigan has synthesized new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked estrogen receptor (ER) targeting moiety reported to be useful for the treatment of breast cancer.
The State University of New York has presented new antibody-drug conjugates (ADCs) consisting of trastuzumab antibody targeting human epidermal growth factor receptor 2 (HER2) covalently linked to Toll-like receptor 7 (TLR7) and/or TLR8 agonists through a linker reported to be useful for the treatment of cancer and infections.
Hillstream Biopharma Inc. has described new salinomycin derivatives acting as angiogenesis inhibitors reported to be useful for the treatment of cancer.
Ambulero Inc., a spinout from the University of Miami Miller School of Medicine, has received a positive response from a type B pre-IND meeting with the FDA on the development of AMB-301 as a treatment for the vascular disease Buerger's disease.
Moleculin Biotech Inc.'s WP-1096 molecule is set to be evaluated in animal studies through the preclinical services offered by the National Institute of Allergy and Infectious Diseases (NIAID).
Cleara Biotech BV has closed a $2.5 million seed financing round, the proceeds of which will be used to progress its compounds toward clinical development and build the company's developmental pipeline.
Researchers from University College Dublin and affiliated organizations presented data from a study that aimed to assess the role of α-melanocyte-stimulatory hormone (α-MSH) in diabetes.
Kupando GmbH has closed a series A funding round raising €13 million. The funds will be used to complete IND-enabling work and to initiate the clinical development of Kupando's lead candidate KUP-101 in a solid tumor indication.
A Surrozen Inc. research team has reported preclinical data for the novel frizzled class receptor 4 (FZD4) agonist, SZN-413, being evaluated for the treatment of diabetic retinopathy. In vitro studies using the Norrin mimetic (SZN-413-p) revealed that SZN-413-p induced Wnt/β-catenin signaling and upregulated blood-brain barrier/blood-retina barrier gene expressions in endothelial cells.
RSS
